Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Schedule of Restricted Cash and Cash Equivalents

The Company’s cash balances as of March 31, 2025 and December 31, 2024 consist of the following:

	March 31, 2025		December 31, 2024
Cash and cash equivalents	$	19,793,799	$	24,372,373
Restricted cash		375,000		375,000
Total cash, cash equivalents, and restricted cash	$	20,168,799	$	24,747,373

Summary of Revenue by Major Source

The following table presents revenue by major source:

	For the Three Months Ended March 31,
	2025		2024
Direct to patient	$	7,807,777	$	2,234,742
Clinical/Medical providers		2,024,037		1,519,647
Total revenue from contracts with customers	$	9,831,814	$	3,754,389

Summary of Potential Common Shares Issuable

Potential dilutive common shares issuable consist of the following at:

	March 31,
	2025		2024
Stock options		22,383		23,929
Restricted stock units		1,190,511		1,197,626
Other warrants		—		668,250
Total		1,212,894		1,889,805